Reset filter
Mots-clés
Auricular Fibrillations ×
Afficher plus Mots-clés
Table des matières
  1. 1. Ensayo clínico
  2. 2. Documentación de rutina
  3. 3. Estudio de registro / cohorte
  4. 4. Seguro de calidad
  5. 5. Estándar de datos
  6. 6. Resultado reportado por el paciente
  7. 7. Especialidad médica
    1. 7.1. Anestesiología
    1. 7.2. Dermatología
    1. 7.3. ENT
    1. 7.4. Geriatría
    1. 7.5. Ginecología / Obstetricia
    1. 7.6. Medicina Interna
      1. Hematología
      1. Enfermedades infecciosas
      1. Cardiología / Angiología
      1. Neumología
      1. Gastroenterología
      1. Nefrología
      1. Endocrinología / Enfermedades metabólicas
      1. Reumatología
    1. 7.7. Neurología
    1. 7.8. Oftalmología
    1. 7.9. Cuidados paliativos
    1. 7.10. Patología / Forense
    1. 7.11. Pediatría
    1. 7.12. Psiquiatría / Psicosomática
    1. 7.13. Radiología
    1. 7.14. Cirugía
      1. Cirugía General / Visceral
      1. Neurocirugía
      1. Cirugía plástica
      1. Cirugía Torácica
      1. Traumatología / Ortopedia
      1. Cirugía vascular
    1. 7.15. Urología
    1. 7.16. Odontología / OMS
Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

35 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

ATRIA Stroke Risk Score

- 25/1/18 - 1 Formulaire, 1 Groupe Item, 9 Eléments de données, 1 Langue
Groupe Item: ATRIA Stroke Risk Score
The ATRIA stroke risk score can be used to optimize optimize anticoagulation decision making in patients with atrial fibrillation (AF) by predicting severe events. Reference: Singer, D. E., Chang, Y., Borowsky, L. H., Fang, M. C., Pomernacki, N. K., Udaltsova, N., ... & Go, A. S. (2013). A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. Journal of the American Heart Association, 2(3), e000250. Publication granted by Daniel E. Singer.

Eligibility Criteria MonDAFIS Atrial Fibrillation in Ischemic Stroke NCT02204267

- 8/1/18 - 1 Formulaire, 2 Groupes Item, 14 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Investigator-initiated prospective randomized multicentre study to uncover the true burden of paroxysmal atrial fibrillation in a representative population of acute stroke patients without known atrial fibrillation. https://clinicaltrials.gov/ct2/show/NCT02204267?term=NCT02204267&rank=1. Sponsor: Charite University, Berlin, Germany; Collaborator: Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma; Information provided by (Responsible Party): Matthias Endres, Charite University, Berlin, Germany

Stroke Secondary to Atrial Fibrillation, NCT01925755 - Eligibility Stroke Secondary to Atrial Fibrillation, NCT01925755

- 28/9/20 - 1 Formulaire, 2 Groupes Item, 9 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Non-interventional Local Study on Prescription Behavior of Anticoagulation Therapy in Secondary Stroke Prevention in Atrial Fibrillation Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01925755

Eligibility Atrial Fibrillation (Prevention of Stroke) NCT02485873

- 22/4/16 - 1 Formulaire, 2 Groupes Item, 8 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Real-Life Evidence on Stroke Prevention in SPAF; ODM derived from: https://clinicaltrials.gov/show/NCT02485873

CHA2DS2-VASc score

- 27/9/21 - 1 Formulaire, 1 Groupe Item, 8 Eléments de données, 1 Langue
Groupe Item: CHADS2
The CHA2DS2-VASc is a simple stroke risk stratification schema for patients with atrial fibrillation which is based on a risk factor approach and provides some improvement in predictive value for TE over the CHADS 2 schema. Reference: Lip, G. Y., Nieuwlaat, R., Pisters, R., Lane, D. A., & Crijns, H. J. (2010). Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest Journal, 137(2), 263-272.

CHADS2 score

- 25/1/18 - 1 Formulaire, 1 Groupe Item, 6 Eléments de données, 1 Langue
Groupe Item: CHADS2
The CHADS2 can quantify risk of stroke for patients who have atrial fibrillation (AF) and may aid in selection of antithrombotic therapy. Reference: Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001). Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. Jama, 285(22), 2864-2870.

Eligibility Atrial Fibrillation NCT01150214

- 30/7/19 - 1 Formulaire, 2 Groupes Item, 11 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
DECAAF: Delayed-Enhancement MRI (DE-MRI) Determinant of Successful Radiofrequency Catheter Ablation of Atrial Fibrillation; ODM derived from: https://clinicaltrials.gov/show/NCT01150214

Eligibility Syncope NCT01965899

- 28/9/21 - 1 Formulaire, 2 Groupes Item, 15 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Usability Study to Assess the Reveal LINQ Insertable Cardiac Monitor System; ODM derived from: https://clinicaltrials.gov/show/NCT01965899

dbGaP phs000974 NHLBI TOPMed: Whole Genome Sequencing and Related Phenotypes in the Framingham Heart Study - Eligibility

- 1/12/23 - 4 Formulaires, 1 Groupe Item, 1 Élément de données, 1 Langue
Groupe Item: IG.elig
Principal Investigator: Vasan Ramachandran, Department of Medicine, Boston University School of Medicine, Boston, MA, USA MeSH: Cardiovascular Diseases,Atherosclerosis,Atrial Fibrillation,Death, Sudden, Cardiac,Diabetes Mellitus, Type 2,Heart Failure,Blood Pressure,Hypertension,Body Mass Index,Adiposity,Lipids,Pulmonary Disease, Chronic Obstructive,Renal Insufficiency, Chronic,Stroke,Osteoporosis,Risk Factors,Biological Markers,Biomarkers, Pharmacological https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000974 The Framingham Heart Study (FHS) is a prospective cohort study of 3 generations of subjects who have been followed up to 65 years to evaluate risk factors for cardiovascular disease. Its large sample of ~15,000 men and women who have been extensively phenotyped with repeated examinations make it ideal for the study of genetic associations with cardiovascular disease risk factors and outcomes. DNA samples have been collected and immortalized since the mid-1990s and are available on ~8000 study participants in 1037 families. These samples have been used for collection of GWAS array data and exome chip data in nearly all with DNA samples, and for targeted sequencing, deep exome sequencing and light coverage whole genome sequencing in limited numbers. Additionally, mRNA and miRNA expression data, DNA methylation data, metabolomics and other 'omics data are available on a sizable portion of study participants. This project will focus on deep whole genome sequencing (mean 30X coverage) in ~4100 subjects and imputed to all with GWAS array data to more fully understand the genetic contributions to cardiovascular, lung, blood and sleep disorders. Comprehensive phenotypic and pedigree data for study participants are available through dbGaP phs000007.

pht004909.v3.p3

1 Groupe Item 2 Eléments de données

pht004910.v4.p3

1 Groupe Item 2 Eléments de données

pht004911.v3.p3

1 Groupe Item 9 Eléments de données

Eligibility Atrial Fibrillation NCT02282098

- 5/12/18 - 1 Formulaire, 2 Groupes Item, 8 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Colchicine in Atrial Fibrillation to Prevent Stroke; ODM derived from: https://clinicaltrials.gov/show/NCT02282098

Eligibility Atrial Fibrillation NCT01976507

- 10/8/19 - 1 Formulaire, 2 Groupes Item, 17 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism; ODM derived from: https://clinicaltrials.gov/show/NCT01976507

Eligibility Atrial Fibrillation NCT02273700

- 20/9/21 - 1 Formulaire, 2 Groupes Item, 16 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Plasma Modifications Associated With Rivaroxaban® Treatment for Stroke Prevention; ODM derived from: https://clinicaltrials.gov/show/NCT02273700

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial